305
Participants
Start Date
November 30, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
May 31, 2014
Alirocumab
Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Rosuvastatin
Rosuvastatin over-encapsulated tablets orally.
Ezetimibe
Ezetimibe over-encapsulated tablets orally.
Placebo
Placebo for alirocumab and ezetimibe.
Chandler
Tucson
Anaheim
Beverly Hills
Fair Oaks
Newport Beach
Northridge
Sacramento
Walnut Creek
Milford
Atlantis
Bradenton
Clearwater
Fort Lauderdale
Jacksonville
Lakeland
(2 Locations), Miami
Oviedo
Pinellas Park
Port Orange
Sarasota
Tampa
West Palm Beach
Winter Park
Boise
Morton
Evansville
Indianapolis
Newton
Overland Park
Wichita
Lexington
Louisville
Auburn
Bethesda
Edina
Rochester
Olive Branch
Port Gibson
St Louis
Butte
Williamsville
Cincinnati
Marion
Portland
Warwick
Greer
Summerville
Kingsport
Dallas
Fort Worth
Houston
Bountiful
Salt Lake City
Herston
New Lambton Heights
Perth
Sherwood
Woolloongabba
Brampton
Burlington
Etobicoke
London
Newmarket
Thornhill
Toronto
Chicoutimi
Dijon
Lille
Bad Oeynhausen
Berlin
Cologne
Regensburg
Ulm
Chieti
Genova
Napoli
Palermo
(2 Locations), Roma
Baja California
Distrito Federal
(3 Locations), Guadalajara
Monterrey
Zapopan Jalisco
(2 Locations), Barcelona
Madrid
Santiago
Seville
West Bromwich
Chester
Peterborough
Salford
Stevenage
Collaborators (1)
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY